KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual Commitments And ObligationsCost Of SalesDevelopment ExpensesEffective Tax Rate %Employees By RegionGross Margin %Gross ProfitIncome Before Income Taxes By RegionInventory BreakdownLong Lived Assets By RegionNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of Total Revenue %OPEX BreakdownProduct Revenue By RegionProduct Revenue By Region %Product Revenue By Region AnnualProduct Revenue By Region Annual %Property And Equipment BreakdownResearch Expenses BreakdownRevenue By Business VerticalRevenue By Business Vertical (Annual)Revenue By Business Vertical AnnualRevenue By Customer (Annual) %Revenue By Location Of Customer (Product)Revenue By Location Of Customer (Product) %Revenue By Location Of Customer (Product Annual)Revenue By Product CategoryRevenue By Product Category %Revenue By Product Category (Annual)Revenue Mix By Business Vertical Annual %Revenue Mix By Product Category (Annual) %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Gross Profit (2016 - 2025)

Vertex Pharmaceuticals has reported Gross Profit over the past 16 years, most recently at $2.7 billion for Q4 2025.

  • Quarterly results put Gross Profit at $2.7 billion for Q4 2025, up 9.46% from a year ago — trailing twelve months through Dec 2025 was $10.4 billion (up 9.07% YoY), and the annual figure for FY2025 was $10.4 billion, up 9.07%.
  • Gross Profit for Q4 2025 was $2.7 billion at Vertex Pharmaceuticals, up from $2.7 billion in the prior quarter.
  • Over the last five years, Gross Profit for VRTX hit a ceiling of $2.7 billion in Q4 2025 and a floor of $1.5 billion in Q1 2021.
  • Median Gross Profit over the past 5 years was $2.2 billion (2023), compared with a mean of $2.1 billion.
  • Biggest five-year swings in Gross Profit: rose 29.25% in 2021 and later grew 2.52% in 2025.
  • Vertex Pharmaceuticals' Gross Profit stood at $1.8 billion in 2021, then grew by 10.64% to $2.0 billion in 2022, then increased by 6.45% to $2.1 billion in 2023, then increased by 15.76% to $2.5 billion in 2024, then grew by 9.46% to $2.7 billion in 2025.
  • The last three reported values for Gross Profit were $2.7 billion (Q4 2025), $2.7 billion (Q3 2025), and $2.6 billion (Q2 2025) per Business Quant data.